Evidence map›Paper›PMID 34187922›Full record

ArticleSaudi medical journal2021

Epidemiology of women diagnosed with breast cancer in Jordan: A 5-year survival analysis and patients' characteristics from 2 public hospitals.

Rimal H Mousa, Jamal M Melhem, Eman A Hammad

Abstract read
In one paragraph

Article in Saudi medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rimal H MousaFrom the Department of Biopharmaceutics and Clinical Pharmacy (Mousa, Hammad); and from the Department of General Surgery (Melhem), Faculty of Medicine-University of Jordan, Amman, Jordan.
Jamal M MelhemFrom the Department of Biopharmaceutics and Clinical Pharmacy (Mousa, Hammad); and from the Department of General Surgery (Melhem), Faculty of Medicine-University of Jordan, Amman, Jordan.
Eman A HammadFrom the Department of Biopharmaceutics and Clinical Pharmacy (Mousa, Hammad); and from the Department of General Surgery (Melhem), Faculty of Medicine-University of Jordan, Amman, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the epidemiology, prognostic factors, and 5-year overall survival (OS) of females with breast cancer (BC) diagnosed between 2011 and 2014 in Jordan.

methodsA retrospective medical review of females who were diagnosed with BC between 2011 and 2014 at the 2 leading public health providers in Jordan was performed. The endpoint of the study was 2018. Data were extracted from the medical files between 2011 and 2018, including demographic clinical data on the patient level. Survival by age, laterality, grade, stage, and treatments modes were calculated by the Kaplan Meier method.

resultsA total of 877 women were included with median age of 51 years and follow-up duration of 2.4 years. Majority of the patients had ductal carcinoma and estrogen receptor (ER) positive type. The 5-year OS for patients with stage I, II, III, and IV, 94%, 86%, and 46% (

conclusionThe incidence in Jordan is increasing, yet survival rates are improving with increased diagnosis during early stages. Therefore, strategies for implementing universal screening programs are advocated to improve clinical outcomes and to reduce the disease burden.

Indexed as

Breast NeoplasmsFemaleHospitals, PublicHumansJordanMiddle AgedNeoplasm StagingPrognosisReceptors, EstrogenRetrospective StudiesSurvival AnalysisSurvival RateReceptors, Estrogenbreast neoplasmepidemiologyJordanprognosissurvival

Identifiers

PMID34187922
PMCPMC9195528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.